Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...
PSADT is vital for monitoring prostate cancer recurrence and guiding treatment decisions, yet often inaccurately calculated by physicians. Inconsistent PSADT documentation can lead to treatment delays ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results